Royalty Pharma Plc
$ 44.65
1.25%
06 Feb - close price
- Market Cap 26,038,733,000 USD
- Current Price $ 44.65
- High / Low $ 44.92 / 43.95
- Stock P/E 25.51
- Book Value 14.95
- EPS 1.75
- Next Earning Report 2026-02-11
- Dividend Per Share $0.87
- Dividend Yield 1.97 %
- Next Dividend Date 2026-03-10
- ROA 0.05 %
- ROE 0.13 %
- 52 Week High 44.92
- 52 Week Low 29.12
About
Royalty Pharma Plc, headquartered in New York, is a leading entity in the biopharmaceutical royalty acquisition arena, specializing in the acquisition of royalties from established market drugs and promising development pipelines. The company's strategic focus on funding innovative therapies not only propels the advancement of biopharmaceutical research but also positions it favorably to generate substantial and diversified revenue streams. With a commitment to optimizing royalty revenues, Royalty Pharma offers institutional investors a unique investment opportunity within the dynamic landscape of pharmaceutical innovation and growth.
Analyst Target Price
$48.10
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-11 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-15 |
| Reported EPS | 1.17 | 1.14 | 1.06 | 0.35 | 0.92 | 0.96 | 0.98 | 1.52 | 0.79 | 0.84 | 1.6 | 1.56 |
| Estimated EPS | 1.04 | 1.03 | 0.95 | 0.25 | 0.93 | 0.97 | 0.98 | 1 | 0.77 | 0.81 | 1.27 | 1.46 |
| Surprise | 0.13 | 0.11 | 0.11 | 0.1 | -0.01 | -0.01 | 0 | 0.52 | 0.02 | 0.03 | 0.33 | 0.1 |
| Surprise Percentage | 12.5% | 10.6796% | 11.5789% | 40% | -1.0753% | -1.0309% | 0% | 52% | 2.5974% | 3.7037% | 25.9843% | 6.8493% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.33 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-13 | 2024-06-14 | 2024-03-15 | 2023-12-15 |
| Amount | $0.235 | $0.22 | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 | $0.21 | $0.21 | $0.2 |
Next Dividend Records
| Dividend per share (year): | $0.87 |
| Dividend Yield | 1.97% |
| Next Dividend Date | 2026-03-10 |
| Ex-Dividend Date | 2026-02-20 |
Recent News: RPRX
2026-02-06 08:29:44
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold over $10.3 million in Class A Ordinary Shares between February 2nd and February 4th, 2026, through multiple transactions ranging from $42.0839 to $43.2928 per share. These sales were executed under a 10b5-1 plan adopted in August 2025. The company also reported a record year for the royalty funding market in 2025, increased its quarterly dividend, and completed a significant acquisition of the Evrysdi royalty.
2026-02-05 20:02:43
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold over $10.3 million worth of Class A Ordinary Shares between February 2nd and February 4th, 2026. These transactions were executed under a pre-arranged 10b5-1 plan. The article also notes recent company achievements, including a record year for the royalty funding market and an increase in its quarterly dividend.
2026-02-05 09:28:56
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold 237,531 Class A Ordinary Shares for over $10.3 million between February 2nd and February 4th, 2026. These transactions were executed via a 10b5-1 plan and represent a significant divestiture. The company recently reported a record year for royalty funding, a dividend increase, and completed a major acquisition, leading to an analyst upgrade from UBS.
2026-02-03 21:29:26
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was executed under a pre-arranged 10b5-1 trading plan. Despite the sale, Royalty Pharma recently announced a record year in royalty funding, increased its quarterly dividend, and made a significant acquisition of royalty rights for the spinal muscular atrophy treatment, Evrysdi.
2026-02-03 21:01:37
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares worth approximately $821,810 on January 30, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a record year in royalty funding, increased its quarterly dividend, and acquired the remaining royalty on the spinal muscular atrophy treatment, Evrysdi, for $240 million upfront.
2026-02-03 20:02:43
Urist Marshall, Executive Vice President, Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This sale was conducted under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma had a record year in royalty funding in 2025, increased its quarterly dividend, and acquired PTC Therapeutics' remaining royalty on Evrysdi for $240 million upfront, prompting UBS to upgrade the stock to Buy.
